『"Breakthrough Malaria Treatments and Vaccines Advance Globally, but Funding Gaps and Inequities Persist"』のカバーアート

"Breakthrough Malaria Treatments and Vaccines Advance Globally, but Funding Gaps and Inequities Persist"

"Breakthrough Malaria Treatments and Vaccines Advance Globally, but Funding Gaps and Inequities Persist"

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

 Malaria remains a global health challenge, and in recent days, several developments have emerged in both the fight against the disease and the ongoing rollout of vaccines. On August 8, it was reported by The World that Ghana has approved the world's first malaria drug specifically for newborns. The medication, called Coartem Baby, is the result of nearly a decade of research and dissolves in breast milk, making it both safe and effective for infants. This marks a major advance in infant malaria care, yet concerns remain as US funding cuts have put crucial malaria research in Africa at risk, leaving experts in Ghana alarmed over a $10 million gap in their malaria elimination budget.

In Uganda, the fight against malaria intensified earlier this year. Seed Global Health highlighted ongoing efforts since April 2025 to integrate the malaria vaccine into child immunization schedules across 105 districts identified with high or moderate transmission. Uganda ranks third in malaria burden among African nations—according to the latest WHO report—and the inclusion of the vaccine is expected to make a significant impact on child mortality and public health. The country’s campaign emphasizes not only delivering the vaccine but also training health workers to build trust within communities and educate caregivers.

Elsewhere on the continent, Rwanda is reconsidering the use of malaria vaccines after a surprise surge in cases following years of progress, as Malaria World reported on August 6. This renewed evaluation includes vaccines that the country had previously declined, showing a growing willingness to adopt new preventive measures as the situation evolves.

Globally, vaccine research continues to push boundaries. On August 7, Malaria World published findings of a new bivalent viral vectored malaria vaccine—the m8Δ vaccine—which offers protection against both Plasmodium falciparum and Plasmodium vivax, effectively targeting two of the most dangerous malaria parasites. This advance is joined by another significant stride announced by WEHI, where researchers used cryo-electron microscopy to reveal a previously unknown region in the malaria parasite’s fertilization complex. Their work identified new domains on proteins Pfs230 and Pfs48/45 as potent vaccine targets, opening the possibility of blocking the parasite’s transmission by up to 99.7 percent.

Commercial deployment of vaccines is also expanding. Novavax, in partnership with Serum Institute of India and Oxford University, announced that its R21/Matrix-M malaria vaccine has sold 20 million doses since its mid-2024 launch, according to the company’s second quarter results released on August 6. The vaccine is addressing urgent needs in malaria-endemic regions, but distribution remains largely concentrated in high-transmission areas, primarily in Africa.

In the United States, malaria remains rare and travel-related, but new developments have arisen. News outlets including the Spokesman-Review and Vax-Before-Travel report a possible first instance of locally transmitted malaria in Washington State—a woman in Pierce County who has not traveled recently was diagnosed earlier this month. If confirmed, this would be the first known case west of the Rockies, and health officials are investigating and testing local mosquitoes. Generally, 2,000 to 2,500 malaria cases are reported annually in the U.S., almost always tied to travel from countries where malaria transmission is active. While Africa has two malaria vaccines available, as of August 7, 2025, these vaccines are not yet available in the United States.

This week’s updates underscore both scientific progress and persistent global obstacles in the malaria fight. The rapid advancement of new vaccines and treatments raises hope, but logistical hurdles, funding challenges, and unequal vaccine access continue to complicate the path towards global malaria elimination.
まだレビューはありません